Epidemiology & Risk Factors

  • Advanced cirrhosis w/ portal HTN and ascites (most common).
  • Acute liver failure.
  • Precipitants: SBP, GI bleeding, excessive diuresis, LVP without albumin replacement, nephrotoxic agents (NSAIDs).
  • Pathogenesis: Portal HTN -> nitric oxide release -> splanchnic vasodilation -> ↓ effective arterial blood volume -> compensatory activation of RAAS/SNS/ADH -> severe renal vasoconstriction -> ↓ GFR.

Clinical Features

  • Signs of portal HTN/cirrhosis: Ascites, jaundice, splenomegaly, caput medusae, spider angiomata.
  • Signs of renal dysfunction: Oliguria or anuria, progressive fluid retention.
  • Hepatic encephalopathy (asterixis, altered mental status).
  • Hypotension (low systemic vascular resistance).

Diagnosis

  • Initial Evaluation: Check serum Cr, electrolytes, urinalysis, and renal US (to rule out structural causes).
  • Key Diagnostic Criteria:
    • Diagnosis of exclusion.
    • Cirrhosis with ascites.
    • AKI (doubling of Cr or Cr > 1.5 mg/dL over < 2 weeks).
    • No improvement after ≥ 48 hours of fluid withdrawal (diuretics held) and albumin challenge (1 g/kg/day). c
      • Unlike crystalloids (which easily leak into the peritoneal space, worsening ascites), albumin remains in the intravascular compartment
      • For HRS, the splanchnic vasodilation and localized renal vasoconstriction are too severe to be overcome by volume expansion alone
    • Absence of shock, nephrotoxic drugs, or parenchymal kidney disease (proteinuria < 500 mg/day, no microhematuria, normal renal US).
  • Key Labs:
    • Urine Na < 10 mEq/L (indicates intense renal sodium retention). c
    • FeNa < 1% (simulates prerenal state).
    • Urine osmolality > serum osmolality.

Differential Diagnostics

  • Prerenal Azotemia: Differentiated by rapid improvement in renal function following volume expansion with IV fluids/albumin.
  • Acute Tubular Necrosis (ATN): Differentiated by urine Na > 40 mEq/L, FeNa > 2%, muddy brown granular casts, and lack of response to albumin.
  • Glomerulonephritis: Differentiated by significant hematuria (> 5 RBCs/hpf), RBC casts, and proteinuria > 500 mg/day.

Management

  1. Immediate/First-Line:
    • Discontinue diuretics (Furosemide, Spironolactone) and nephrotoxic drugs.
    • Initiate Albumin infusion (1 g/kg on day 1, then 20-40 g/day) + vasoconstrictor therapy.
    • Terlipressin (preferred systemic vasoconstrictor; analogue of vasopressin).
    • Norepinephrine (alternative if pt in ICU).
    • Midodrine (alpha-1 agonist) + Octreotide (somatostatin analogue) (used if Terlipressin is unavailable).
  2. Refractory/Second-Line:
    • TIPS: Reduces portal pressure; used in selected pts as a bridge to transplant.
    • Renal replacement therapy (hemodialysis) if pt meets urgent indications (AEIOU) and is a transplant candidate.
  3. Definitive Therapy:
    • Orthotopic liver transplantation (OLT) (only curative treatment).

Complications

  • Refractory ascites.
  • Severe electrolyte derangements (hyponatremia, hyperkalemia).
  • Multi-organ dysfunction syndrome (MODS).
  • High short-term mortality (especially HRS-AKI without treatment).